These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 12139368

  • 1. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
    Poirier J.
    Int J Clin Pract Suppl; 2002 Jun; (127):6-19. PubMed ID: 12139368
    [Abstract] [Full Text] [Related]

  • 2. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F.
    Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
    Rösler M.
    Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR.
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.
    Drugs Aging; 2004 Jun; 21(7):453-78. PubMed ID: 15132713
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Have cholinergic therapies reached their clinical boundary in Alzheimer's disease?
    Jones RW.
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S7-S13. PubMed ID: 12973745
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
    Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, Gallai V.
    Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
    [Abstract] [Full Text] [Related]

  • 16. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).
    Maelicke A.
    Int J Clin Pract Suppl; 2001 May; (120):24-8. PubMed ID: 11406923
    [Abstract] [Full Text] [Related]

  • 17. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R.
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.